Barclays PLC holds 7.84% of Forward Air Corp | FWRD SEC Filing
schemaVersion: CUSIP Number(s): 34986A104 1Names of Reporting Persons Barclays PLC 2Check the appropriate box if a member of…
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint OCALA, Fla.,…